Novavax’s potential vaccine to prevent Covid-19 generated a promising immune response in an early-stage clinical trial, the U.S.-based biotech firm announced Tuesday.
The phase one trial included 131 healthy participants between ages 18 and 59 at two sites in Australia. Novavax said 106 participants received one of four dose levels of the potential vaccine, named NVX-CoV2373, with or without an adjuvant, which is an ingredient designed to enhance the immune response. The remaining 25 patients received a placebo.
Participants received two doses of the potential vaccine via intramuscular injection approximately 21 days apart, the company said.
The vaccine produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, and killer T-cells, the company said. Additionally, the neutralizing antibodies that were produced were higher than those seen in people who have recovered from Covid-19, the company said. The immune response was also stronger for those who had the adjuvant, the company said.
Novavax said the vaccine was well tolerated with no serious adverse events reported. Most patients reported tenderness and pain at the injection after the first dose, with some patients also reporting headaches, fatigue or muscle aches. Only one participant in the trial experienced a mild fever after a second dose, the company said. Eight patients had reactions that required hospitalizations, though they were resolved after a few days.
Despite the data, shares of the company were down as much as 32% in after-hours trading.
https://www.cnbc.com/2020/08/04/novavaxs-coronavirus-vaccine-shows-promise-in-early-stage-trial.html
